10% Over 65 Battle Alzheimer’s; Treatment for Early Stage Reversal Posed

Alzheimer’s disease, dementia, and other cognitive decline conditions are sweeping the nation. Now the sixth leading cause of death in the United States, Alzheimer’s disease closely rivals the death toll claimed by heart disease and cancer, with more recent analyses projecting that it will soon be the third leading cause of death. Conventional medicine has little resolution and an even poorer prognosis for patients stricken with this diagnosis, but one local Birmingham provider has had enough.

Author of Diabetes Delusion: Break Through to Reverse Type 2 Diabetes, Thyroid Delusion: Break Through to Reverse Your Thyroid Condition, and The Alzheimer’s Survival Guide: How You Can Take Control of Alzheimer’s and Get Your Life Back, and lead functional medicine practitioner at the Integrative Health Center of Alabama, Dr. Jason Koenig, DC, IFMCP, refuses to accept the fate mainstream doctors prescribe to his patients. He has worked with countless patients to reverse “irreversible” chronic diseases like type 2 diabetes, hypothyroidism, and autoimmune conditions, and he continues to work with them daily to educate them about nutrition, reestablish healthy habits, and make essential lifestyle modifications that support the body’s innate ability to heal and thrive. Seeing what a huge success his patients have had, Dr. Koenig has recently expanded his practice to offer treatment to individuals battling cognitive decline disorders such as Alzheimer’s and dementia.

His extensive expertise and his proven track record paired with his credentials and continued education have made him one of the most sought-after doctors in the field of functional medicine in the state of Alabama. He holds his IFMCP certification through the Institute of Functional Medicine, making him one of only three health care practitioners in the state of Alabama to hold the certification — and the only health care practitioner equipped to treat cognitive decline patients to hold the certification. Dr. Koenig is dedicated to challenging the status quo of health care and restoring his patients’ sense of hope.

It is encouraged that anyone interested in obtaining optimal results with IHCAL makes the commitment to restore his or her health before the progression of the disease reaches a truly irreversible stage. The office continues to offer free informative events as well as consultations that allow prospective patients to learn about the clinic’s unique approach. Interested individuals may contact the clinic directly at 205-994-7313 or visit the IHCAL website. Learn more at https://www.ihcal.com.

IHCAL is a Birmingham, Alabama-based functional medicine practice specializing in the treatment and reversal of chronic diseases like type 2 diabetes, hypothyroidism, autoimmune disease, and cognitive decline disorders including Alzheimer’s disease and dementia. Dedicated to supporting the body’s innate ability to regenerate and heal when adequately supported, the clinic builds customized care plans that are designed to educate patients and facilitate lifestyle modification so that they can feel comfortable in becoming informed advocates for their health care decisions while reclaiming a renewed quality of life.

https://www.biospace.com/article/releases/10-percent-of-adults-over-65-are-battling-alzheimer-s-birmingham-clinic-offers-breakthrough-treatment-for-early-stage-disease-reversal/

Recro Pharma gains on planned resubmission of IV meloxicam NDA

Thinly traded micro cap Recro Pharma (NASDAQ:REPH) is up 14% premarket on average volume in response to its announcement that, based on its meeting with the FDA, it will refile its marketing application for IV meloxicam by the end of the month. The revised NDA will incorporate revised language related to labeling and additional information on extractable and leachable items.

The company received a CRL in May citing data from ad hoc analyses and selected secondary endpoints that undermined its claimed efficacy.

Previously: FDA rejects Recro Pharma’s marketing application for IV meloxicam (May 24)

https://seekingalpha.com/news/3387421-recro-pharma-14-percent-premarket-planned-resubmission-iv-meloxicam-nda

Boston Scientific upgraded to Buy from Hold at Jefferies

Jefferies analyst Raj Denhoy upgraded Boston Scientific to Buy and raised his price target for the shares to $42 from $34.

https://thefly.com/landingPageNews.php?id=2784871

Weight Watchers initiated at Goldman Sachs

Weight Watchers initiated with a Neutral at Goldman Sachs. Goldman Sachs analyst Jason English started Weight Watchers International with a Neutral rating and $73 price target. The analyst expects strong subscriber growth from the company but views the valuation as full at current share levels.

https://thefly.com/landingPageNews.php?id=2784879

Piper remains buyer of Deciphera ahead of update on DCC2618

Piper Jaffray analyst Christopher Raymond remains a buyer of Deciphera Pharmaceuticals ahead of a “key” update for lead compound DCC2618 at this year’s European Society for Medical Oncology meeting. The analyst likes the near-term setup for the shares and keeps an Overweight rating on the name with a $50 price target. He thinks DCC2618’s “strong and competitive safety/efficacy profile” will “continue to hold up” at ESMO. Further, Raymond sees additional catalysts for Deciphera shares in 2019.

https://thefly.com/landingPageNews.php?id=2784881

United Therapeutics and MannKind enter into exclusive licensing agreement

United Therapeutics (UTHR) and MannKind (MNKD) announced that they have entered into a worldwide exclusive licensing and collaboration agreement for the development and commercialization of a dry powder formulation of treprostinil, an investigational product currently being evaluated in clinical trials for the treatment of pulmonary arterial hypertension. Under the agreement, United Therapeutics will be responsible for global development, regulatory and commercial activities. MannKind will manufacture clinical supplies and initial commercial supplies of the product at its manufacturing facility in Danbury, Connecticut. Long-term commercial supplies will be manufactured by United Therapeutics. Under the terms of the agreement, MannKind will receive an upfront payment of $45M and potential milestone payments of up to $50M, dependent upon the achievement of specific development targets. MannKind will also be entitled to receive low double-digit royalties on net sales of the product. In addition, MannKind granted United Therapeutics an option to expand the license to include other active ingredients for the treatment of pulmonary hypertension. Each optioned product would be subject to the payment to MannKind of up to $40M in additional option exercise and development milestone payments as well as a low double-digit royalty on net sales of any such product. The parties also entered into a research agreement for the conduct of research by MannKind on behalf of United Therapeutics for products outside the scope of the licensing and collaboration agreement. MannKind will receive an immediate payment of $10M in consideration for its performance under the research agreement.

https://thefly.com/landingPageNews.php?id=2784905

WellCare sees Meridian acquisition accretive to FY19 EPS by 40c-50c

WellCare Health Plans announced that, effective September 1, it completed its acquisition of Meridian Health Plan of Michigan, Meridian Health Plan of Illinois, and MeridianRx, a pharmacy benefit manager following the receipt of all required regulatory approvals. With the closing of the acquisition, Meridian is now a wholly-owned subsidiary of WellCare. The transaction is expected to produce 40c-50c of accretion to WellCare’s adjusted EPS in 2019, 70c-80c of accretion in 2020, and $1.00+ of accretion in 2021, inclusive of $30M-$40M in synergies that will ramp up over the next few years and exclusive of one-time transaction-related expenses of $75M-$85M and cumulative integration-related expenses of $50M-$60M.

https://thefly.com/landingPageNews.php?id=2784911